Aimabs Corporation

Accelerating Global Access to Transformative Medicines

Aimabs is a biopharmaceutical company built to bridge global innovation and patient access. We partner across borders to advance and deliver transformative medicines, bringing high-impact therapies to patients with greater speed, clarity, and confidence.

With deep roots in targeted monoclonal antibody innovation, Aimabs has expanded into multiple therapeutic modalities and integrates advanced AI-enabled approaches to streamline development. Our primary focus areas include hematology, oncology, and other specialty indications with significant unmet medical need.

What sets Aimabs apart is our integrated, end-to-end capability across regulatory strategy, clinical development, and commercialization, supported by bidirectional global-local execution that connects scientific innovation to real-world clinical impact.

Mission

Core Advantages

Regulatory Excellence

(U.S.–China and Global Alignment)

Regulatory strategy is a defining strength at Aimabs. Our leadership has first-hand experience within top global agencies and deep expertise navigating China’s evolving regulatory landscape. This dual perspective allows us to de-risk development, accelerate timelines, and align programs with global standards from the earliest stages.

Drug Development Expertise

(End-to-End, Early-to-Late Stage)

Aimabs brings decades of hands-on experience across all stages of drug development, from early discovery through late-stage validation and launch preparation. We combine scientific rigor, clinical insight, and operational excellence to improve execution quality and increase probability of success.

Commercialization and Global Partnership Capability

Aimabs supports both inbound and outbound commercialization strategies through a highly execution-driven partnership model.

Aimabs partners with CiNS, a leading oncology/hematology-focused commercial organization in Greater China, trusted by multinational companies including Eli Lilly, Pierre Fabre, and Otsuka.

Learn More

Global Expertise, China Execution

Yaping Wang, PhD

Founder & CEO

• Former FDA Senior Reviewer (Hematology & Oncology)

• Deep expertise in clinical study design & regulatory strategy

• Led global registration pathways for oncology products in U.S. & China

• Committee member of International Regulatory Science Specialty Committee

• Co-founder and chair of ASA Regulatory-Industry Statistics Workshop

Regulatory

Michael Humphries, FRCP

SVP, Chief Medical Officer

• Former CSO and medical director of Novartis

• 30+ years of experience in all phases of clinical development in China/AP

• Contributed to 50+ NDA approvals in China and many others in AP

• Built several development organizations up from scratch in both MNC’s and small biotechs

Jean Zhang, MD

VP, Clinical Operations

• Former Development QA Head at Novartis Oncology

• 30+ years at Novartis, Pfizer, AstraZeneca.

• Key roles launching BRILIQUE, JAKAVI, ZYKADIA in China.

• Expert in clinical QA, operations & PV systems

Clinical Development

Jonathan Zhu

SVP, Chief Commercial Officer

• Former Head of Sales & Marketing of China at Celgene, Sanofi, and Novartis

• 30+ years in hematology, oncology & rare disease commercialization

• Led Olverembatinib, REVLIMID, ABRAXANE launches in China

• Expert in pricing, reimbursement & access

Commercialization & Market Access

Global Expertise, China Execution